Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced it has delivered the first of two 5G mobile filters to a tier-1 RF component customer, signifying a crucial step in its expansion into the 5G market. The filters utilize advanced wafer-level packaging technology and will support 5G/WiFi coexistence. The second filter is expected to ship in Q4 2021. Akoustis aims to increase annual production capacity to 500 million filters by the end of 2021, driven by rising demand in the 5G and WiFi markets. CEO Jeff Shealy highlighted the significance of this shipment for revenue and unit volume growth.
Akoustis Technologies (NASDAQ: AKTS) reported a remarkable 270% year-over-year revenue growth, achieving $6.6 million for the fiscal year ending June 30, 2021. The Q4 revenue of $2.2 million aligns with previous guidance despite challenges from COVID-19 and semiconductor supply chain issues. The company maintains $88.3 million in cash and anticipates strong demand for its XBAW filters in 5G and WiFi markets, aiming for double-digit sequential revenue growth in the upcoming quarter. Akoustis also announced plans to increase production capacity significantly.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced the receipt of a volume commercial order for its patented WiFi 6 XBAW™ filters from its second WiFi 6 OEM customer. The order includes 5.2 GHz and 5.6 GHz filters designed for a new MU-MIMO router platform, with shipments expected to start in the current quarter. The company anticipates ramping production in Q4 2021, capitalizing on significant market opportunities in WiFi 6 and WiFi 6E. Akoustis is planning to increase its production capacity to 500 million filters annually by the end of 2021.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced the design of its patented XBAW filters into a new WiFi 6E gateway platform for a carrier-grade OEM. The 5.5 GHz and 6.5 GHz coexistence filters will enable advanced multi-user capabilities. Production is expected to ramp up in early 2022. Akoustis aims to increase its production capacity to 500 million filters per year by the end of 2021, driven by a growing sales funnel. The FCC's approval for the 5.9 to 7.1 GHz spectrum further fuels demand for high-performance RF filters.
Akoustis Technologies announced the appointment of Kamran Cheema as Vice President of Engineering, effective August 18, 2021. Cheema brings over 25 years of RF experience from leading companies such as Qualcomm and TDK. He will lead 5G mobile filter and multi-chip-module development, while also aiding in wafer-level packaging deployment for 5G smartphones. Akoustis is ramping up production capacity to approximately 500 million filters annually by year-end 2021, with an expanding product catalog of RF filters aimed at 5G and WiFi 6E markets.
On August 16, 2021, Akoustis Technologies (NASDAQ: AKTS) announced an investor update call scheduled for August 30, 2021, at 8:00 a.m. ET. The call aims to provide a business update and future outlook, including a Q&A session. The company is ramping up production capacity at its New York facility to 500 million filters annually by year-end 2021. Akoustis is actively producing WiFi 6 filters and shipping 5G small cell XBAW filters, while expanding its product catalog to include new WiFi 6E coexistence solutions.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the 24th Annual Oppenheimer Technology, Internet, and Communications Conference, taking place virtually from August 9-11, 2021. Management will present on August 9 at 1:15 pm ET, accessible via their investor relations website. The company is ramping up production capacity to 500 million filters per year by the end of 2021 due to increased demand in 5G mobile and WiFi 6E markets. Akoustis currently offers 15 commercial XBAW filters, with plans to introduce two new WiFi 6E modules, expanding their catalog to 17.
Akoustis Technologies (NASDAQ: AKTS) announced design wins and a volume pre-production order for its 3.6 GHz XBAW filters aimed at 5G network infrastructure, such as base stations and customer premise equipment (CPE). These filters will enhance last-mile connectivity through superior selectivity performance. Production is expected to ramp in early 2022, following volume pre-production shipments in Q3 2021. The company is engaged with over 10 CBRS equipment makers and aims to boost annual production capacity to 500 million filters by end of 2021.
Akoustis Technologies is expanding its technology capabilities by developing an integrated diplexer for personal computers, laptops, tablets, and other mobile devices. This initiative stems from a development order received from a tier-1 chipset maker for the WiFi 6E diplexer, which will utilize Akoustis' proprietary XBAW® filter technology. The first samples are expected to ship by Q1 2022, marking a significant step in enhancing the company's product portfolio and addressing market demands for size reduction and spectrum selectivity in high-performance wireless applications.
Akoustis Technologies (NASDAQ: AKTS) has signed a foundry agreement to produce its patented XBAW® filters for 5G mobile smartphones and other wireless devices. Manufacturing will occur at its facility in Canandaigua, NY, with volume production expected to ramp up in the second half of 2022. The agreement follows successful evaluation of initial samples provided to the customer. Akoustis aims to increase its production capacity to 500 million filters annually by the end of 2021, targeting significant growth in the mobile BAW filter market.